22-06-2007 Positive EU opinion
Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar
- European approval would provide patients suffering from low red blood cells and healthcare payors access to a high quality, cost-effective treatment
- Sandoz at the forefront of bringing follow-on biological medicines to patients worldwide following precedent-setting approval of Omnitrope in 2006
- Sandoz pipeline includes several biosimilar projects for other leading biotech medicines
